KRAS and neoplasm: For instance, it has been clarified that ligands of VDAC proteins selectively induce non-apoptotic cell death in tumor cells harbouring mutations in the oncogenes HRAS, KRAS, or BRAF by comparing the binding proteins of erastin A6 and erastin B2, an erastin analogue that lacks its activity [32].